# Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

> **NCT00356889** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Cholangiocarcinoma of the Gallbladder
- Gastrointestinal Cancer
- Recurrent Extrahepatic Bile Duct Cancer
- Recurrent Gallbladder Cancer
- Unresectable Extrahepatic Bile Duct Cancer
- Unresectable Gallbladder Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00356889
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-10
- **Final completion:** 2010-06
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356889, "Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00356889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*